Aquestive Therapeutics, Inc. Shareholders' Equity
Aquestive Therapeutics, Inc. (AQST) had Shareholders' Equity of -$56.59 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-11
- 2026-06-30: Stockholders' Equity Attributable to Parent -$56.59M.
- 2026-03-31: Stockholders' Equity Attributable to Parent -$34.05M.
- 2025-12-31: Stockholders' Equity Attributable to Parent -$33.66M.
- 2025-09-30: Stockholders' Equity Attributable to Parent -$4.11M.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | -$56.59M 10-Q · filed 2026-08-11 | |
| 2026-03-31 | -$34.05M 10-Q · filed 2026-08-11 | |
| 2025-12-31 | -$33.66M 10-Q · filed 2026-08-11 | |
| 2025-09-30 | -$4.11M 10-Q · filed 2025-11-05 | |
| 2025-06-30 | -$72.59M 10-Q · filed 2026-08-11 | |
| 2025-03-31 | -$60.93M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | -$60.16M 10-Q · filed 2026-08-11 | |
| 2024-09-30 | -$45.42M 10-Q · filed 2025-11-05 | |
| 2024-06-30 | -$35.48M 10-Q · filed 2025-11-05 | |
| 2024-03-31 | -$36.30M 10-Q · filed 2025-11-05 | |
| 2023-12-31 | -$106.49M 10-K · filed 2026-03-04 | |
| 2023-09-30 | -$102.93M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | -$106.65M 10-Q · filed 2024-11-04 | |
| 2023-03-31 | -$109.23M 10-Q · filed 2024-11-04 | |
| 2022-12-31 | -$118.55M 10-K · filed 2025-03-05 | |
| 2022-09-30 | -$107.82M 10-Q · filed 2023-11-06 | |
| 2022-06-30 | -$96.36M 10-Q · filed 2023-11-06 | |
| 2022-03-31 | -$93.14M 10-Q · filed 2023-11-06 | |
| 2021-12-31 | -$82.13M 10-K · filed 2024-03-05 | |
| 2021-09-30 | -$60.34M 10-Q · filed 2022-11-01 | |
| 2021-06-30 | -$53.77M 10-Q · filed 2022-11-01 | |
| 2021-03-31 | -$51.80M 10-Q · filed 2022-11-01 | |
| 2020-12-31 | -$48.50M 10-K · filed 2023-03-31 | |
| 2020-09-30 | -$36.52M 10-Q · filed 2021-11-02 | |
| 2020-06-30 | -$21.39M 10-Q · filed 2021-11-02 | |
| 2020-03-31 | -$20.83M 10-Q · filed 2021-11-02 | |
| 2019-12-31 | -$6.12M 10-K · filed 2022-03-08 | |
| 2019-09-30 | -$34.46M 10-Q · filed 2020-11-04 | |
| 2019-06-30 | -$24.66M 10-Q · filed 2020-11-04 | |
| 2019-03-31 | -$6.06M 10-Q · filed 2020-11-04 | |
| 2018-12-31 | $10.08M 10-K · filed 2021-03-09 | |
| 2018-09-30 | $23.44M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | -$38.95M 10-Q · filed 2019-11-05 | |
| 2018-03-31 | -$22.40M 10-Q · filed 2019-11-05 | |
| 2017-12-31 | -$26.50M 10-K · filed 2020-03-11 | -$68.60M 10-Q · filed 2018-09-04 |
| 2016-12-31 | -$57.20M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |